Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma

Frontiers in Immunology

Volumn 5, Issue JUN, 2014, Pages

  Tete, Sarah M ^a,b   Bijl, Marc ^c   Sahota, Surinder S ^b   Bos, Nicolaas A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c MARTINI HOSPITAL   (Netherlands)

Author keywords

Immune defects; Infections; MGUS; Multiple myeloma; Vaccination

Indexed keywords

EID: 84905658872     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00257     Document Type: Review

References (181)

1. Yoshikawa TT. Epidemiology and unique aspects of aging and infectious diseases. Clin Infect Dis (2000) 30:931-3. doi: 10.1086/313792
2. Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood (2009) 113:5412-7. doi:10.1182/blood-2008-12-194241
3. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med (2006) 354:1362-9. doi:10.1056/NEJMoa054494
4. Blade J, Rosinol L, Cibeira MT, de Larrea CF. Pathogenesis and progression of monoclonal gammopathy of undetermined significance. Leukemia (2008) 22:1651-7. doi:10.1038/leu.2008.203
5. Eisele L, Durig J, Huttmann A, Duhrsen U, Assert R, Bokhof B, et al. Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain MGUS in Germany. Ann Hematol (2012) 91:243-8. doi:10.1007/s00277-011-1293-1
6. Dispenzieri A, Katzmann JA, Kyle RA, Larson DR, Melton LJ III, Colby CL, et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet (2010) 375:1721-8. doi:10.1016/S0140-6736(10)60482-5
7. Weiss B, Abadie J, Verma P, Howard R, Kuehl W. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood (2009) 113:5418-22. doi:10.1182/blood-2008-12-195008
8. Rajkumar SV, Kyle RA, Therneau TM, Melton LJ III, Bradwell AR, Clark RJ, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood (2005) 106:812-7. doi:10.1182/blood-2005-03-1038
9. Landgren O, Albitar M, Ma W, Abbasi F, Hayes RB, Ghia P, et al. B-cell clones as early markers for chronic lymphocytic leukemia. Mayo Clin Proc (2009) 360:659-67. doi:10.1056/NEJMoa0806122
10. Pfeifer S, Perez-Andres M, Ludwig H, Sahota SS, Zojer N. Evaluating the clonal hierarchy in light-chain multiple myeloma: implications against the myeloma stem cell hypothesis. Leukemia (2011) 25:1213-6. doi:10.1038/leu.2011.70
11. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol (2003) 121:749-57. doi:10.1046/j.1365-2141.2003.04355.x
12. Blade J, Lopez-Guillermo A, Rozman C, Cervantes F, Salgado C, Aguilar JL, et al. Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. Br J Haematol (1992) 81:391-4. doi:10.1111/j.1365-2141.1992.tb08245.x
13. Dhodapkar MV, Geller MD, Chang DH, Shimizu K, Fujii S, Dhodapkar KM, et al. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med (2003) 197:1667-76. doi:10.1084/jem.20021650
14. Dhodapkar MV, Krasovsky J, Osman K, Geller MD. Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J Exp Med (2003) 198:1753-7. doi:10.1084/jem.20031030
15. Spisek R, Kukreja A, Chen LC, Matthews P, Mazumder A, Vesole D, et al. Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J Exp Med (2007) 204:831-40. doi:10.1084/jem.20062387
16. Perez-Andres M, Santiago M, Almeida J, Mateo G, Porwit-MacDonald A, Bjorklund E, et al. Immunophenotypic approach to the identification and characterization of clonal plasma cells from patients with monoclonal gammopathies. J Biol Regul Homeost Agents (2004) 18:392-8.
17. Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med (2007) 356:2582-90. doi:10.1056/NEJMoa070389
18. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood (2008) 111:2516-20. doi:10.1182/blood-2007-10-116129
19. Kastritis E, Zervas K, Symeonidis A, Terpos E, Delimbassi S, Anagnostopoulos N, et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia (2009) 23:1152-7. doi:10.1038/leu.2008.402
20. Kristinsson SY, Tang M, Pfeiffer RM, Bjorkholm M, Goldin LR, Blimark C, et al. Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. Haematologica (2012) 97:854-854. doi:10.3324/haematol.2011.054015
21. Kristinsson SY, Bjorkholm M, Andersson TM, Eloranta S, Dickman PW, Goldin LR, et al. Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. Haematologica (2009) 94:1714-20. doi:10.3324/haematol.2009.010066
22. Karlsson J, Andreasson B, Kondori N, Erman E, Riesbeck K, Hogevik H, et al. Comparative study of immune status to infectious agents in elderly patients with multiple myeloma, Waldenstrom's macroglobulinemia, and monoclonal gammopathy of undetermined significance. Clin Vaccine Immunol (2011) 18:969-77. doi:10.1128/CVI.00021-11
23. Mills K, Cawley J. Abnormal monoclonal antibody-defined helper/suppressor T-cell subpopulations in multiple myeloma: relationship to treatment and clinical stage. Br J Haematol (1983) 53:271-5. doi:10.1111/j.1365-2141.1983.tb02021.x
24. Saba H, Hartmann R, Herion J. Hemophilus influenzae septicemia and polyarthritis in multiple myeloma. South Med J (1979) 72:743-6.
25. Schutt P, Brandhorst D, Stellberg W, Poser M, Ebeling P, Muller S, et al. Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. Leuk Lymphoma (2006) 47:1570-82. doi:10.1080/10428190500472503
26. Augustson B, Begum G, Dunn J, Barth N, Davies F, Morgan G, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 - Medical Research Council Adult Leukaemia Working Party. J Clin Oncol (2005) 23:9219-26. doi:10.1200/JCO.2005.03.2086
27. Savage D, Lindenbaum J, Garrett T. Biphasic pattern of bacterial infection in multiple myeloma. Ann Intern Med (1982) 96:47-50. doi:10.7326/0003-4819-96-1-47
28. Shaikh B, Lombard R, Appelbaum P, Bentz M. Changing patterns of infections in patients with multiple myeloma. Oncology (1982) 39:78-82. doi:10.1159/000225611
29. Rayner HC, Haynes AP, Thompson JR, Russell N, Fletcher J. Perspectives in multiple myeloma: survival, prognostic factors and disease complications in a single centre between 1975 and 1988. Q J Med (1991) 79:517-25.
30. Jacobson D, Zolla-Pazner S. Immunosuppression and infection in multiple myeloma. Semin Oncol (1986) 13:282-90.
31. Palumbo A, Dimopoulos M, San Miguel J, Harousseau J, Attal M, Hussein M, et al. Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. Blood Rev (2009) 23:87-93. doi:10.1016/j.blre.2008.07.003
32. Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol (2012) 87:78-88. doi:10.1002/ajh.22237
33. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet (2006) 367:825-31. doi:10.1016/S0140-6736(06)68338-4
34. Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis (2009) 49:1211-4. doi:10.1086/605664
35. Chanan-Khan A, Sonneveld P, Schuster M, Stadtmauer E, Facon T, Harousseau J, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol (2008) 26:4784-6. doi:10.1200/JCO.2007.14.9641
36. Cesana C, Nosari AM, Klersy C, Miqueleiz S, Rossi V, Ferrando P, et al. Risk factors for the development of bacterial infections in multiple myeloma treated with two different vincristine-adriamycin-dexamethasone schedules. Haematologica (2003) 88:1022-8.
37. Shustik C, Belch A, Robinson S, Rubin SH, Dolan SP, Kovacs MJ, et al. A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7. Br J Haematol (2007) 136:203-11. doi:10.1111/j.1365-2141.2006.06405.x
38. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol (2010) 11:29-37. doi:10.1016/S1470-2045(09)70284-0
39. Jego G, Bataille R, Geffroy-Luseau A, Descamps G, Pellat-Deceunynck C. Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia (2006) 20:1130-7. doi:10.1038/sj.leu.2404226
40. Bohnhorst J, Rasmussen T, Moen S, Fløttum M, Knudsen L, Børset M, et al. Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia (2006) 20:1138-44. doi:10.1038/sj.leu.2404225
41. Harwood NE, Batista FD. Early events in B cell activation. Annu Rev Immunol (2010) 28:185-210. doi:10.1146/annurev-immunol-030409-101216
42. Deenick EK, Ma CS, Brink R, Tangye SG. Regulation of T follicular helper cell formation and function by antigen presenting cells. Curr Opin Immunol (2011) 23:111-8. doi:10.1016/j.coi.2010.10.007
43. Frasca D, Landin AM, Riley RL, Blomberg BB. Mechanisms for decreased function of B cells in aged mice and humans. J Immunol (2008) 180:2741-6. doi:10.4049/jimmunol.180.5.2741
44. Wikby A, Johansson B, Ferguson F, Olsson J. Age-related changes in immune parameters in a very old population of Swedish people: a longitudinal study. Exp Gerontol (1994) 29:531-41. doi:10.1016/0531-5565(94)90036-1
45. Olsson J, Wikby A, Johansson B, Löfgren S, Nilsson B, Ferguson FG. Age-related change in peripheral blood T-lymphocyte subpopulations and cytomegalovirus infection in the very old: the Swedish longitudinal OCTO immune study. Mech Ageing Dev (2001) 121:187-201. doi:10.1016/S0047-6374(00)00210-4
46. Siegrist CA, Aspinall R. B-cell responses to vaccination at the extremes of age. Nat Rev Immunol (2009) 9:185-94. doi:10.1038/nri2508
47. Shi Y, Yamazaki T, Okubo Y, Uehara Y, Sugane K, Agematsu K. Regulation of aged humoral immune defense against pneumococcal bacteria by IgM memory B cell. J Immunol (2005) 175:3262-7. doi:10.4049/jimmunol.175.5.3262
48. Colonna-Romano G, Bulati M, Aquino A, Pellicanò M, Vitello S, Lio D, et al. A double-negative (IgD- CD27) B cell population is increased in the peripheral blood of elderly people. Mech Ageing Dev (2009) 130:681-90. doi:10.1016/j.mad.2009.08.003
49. Caraux A, Klein B, Paiva B, Bret C, Schmitz A, Fuhler GM, et al. Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138- and CD138 plasma cells. Haematologica (2010) 95:1016-20. doi:10.3324/haematol.2009.018689
50. Rubtsov AV, Rubtsova K, Fischer A, Meehan RT, Gillis JZ, Kappler JW, et al. Toll-like receptor 7 (TLR7)-driven accumulation of a novel CD11c B-cell population is important for the development of autoimmunity. Blood (2011) 118:1305-15. doi:10.1182/blood-2011-01-331462
51. Kruetzmann S, Rosado MM, Weber H, Germing U, Tournilhac O, Peter H, et al. Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J Exp Med (2003) 197:939-45. doi:10.1084/jem.20022020
52. Frasca D, Blomberg BB. Aging affects human B cell responses. J Clin Immunol (2011) 31:430-5. doi:10.1007/s10875-010-9501-7
53. Ademokun A, Wu YC, Martin V, Mitra R, Sack U, Baxendale H, et al. Vaccination-induced changes in human B-cell repertoire and pneumococcal IgM and IgA antibody at different ages. Aging Cell (2011) 10:922-30. doi:10.1111/j.1474-9726.2011.00732.x
54. Gibson KL, Wu YC, Barnett Y, Duggan O, Vaughan R, Kondeatis E, et al. B-cell diversity decreases in old age and is correlated with poor health status. Aging Cell (2009) 8:18-25. doi:10.1111/j.1474-9726.2008.00443.x
55. Murasko DM, Bernstein ED, Gardner EM, Gross P, Munk G, Dran S, et al. Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp Gerontol (2002) 37:427-39. doi:10.1016/S0531-5565(01)00210-8
56. Bernstein E, Kaye D, Abrutyn E, Gross P, Dorfman M, Murasko DM. Immune response to influenza vaccination in a large healthy elderly population. Vaccine (1999) 17:82-94. doi:10.1016/S0264-410X(98)00117-0
57. Beyer WE, Palache AM, Baljet M, Masurel N. Antibody induction by influenza vaccines in the elderly: a review of the literature. Vaccine (1989) 7:385-94. doi:10.1016/0264-410X(89)90150-3
58. Iorio AM, Rivosecchia P, Zeia T, Neria M, Merletti L. Immune response to trivalent inactivated influenza vaccine in young and elderly subjects. Vaccine (1989) 7:341-4. doi:10.1016/0264-410X(89)90198-9
59. Demicheli V, Di Pietrantonj C, Jefferson T, Rivetti A, Rivetti D. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev (2007) 2:CD001269. doi:10.1002/14651858.CD001269.pub3
60. Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA (1994) 272:1661-5. doi:10.1001/jama.272.21.1661
61. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine (2006) 24:1159-69. doi:10.1016/j.vaccine.2005.08.105
62. Sasaki S, Sullivan M, Narvaez CF, Holmes TH, Furman D, Zheng NY, et al. Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. J Clin Invest (2011) 121:3109-19. doi:10.1172/JCI57834
63. Stein KE. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis (1992) 165(Suppl 1):S49-52. doi:10.1093/infdis/165-Supplement_1-S49
64. Käyhty H, Karanko V, Peltola H, Mäkelä P. Serum antibodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and responses to reimmunization: no evidence of immunologic tolerance or memory. Pedriatics (1984) 24:857-8.
65. Chu C, Schneerson R, Robbins JB, Rastogi SC. Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates. Infect Immun (1983) 40:245-56.
66. Granoff DM, Rathore MH, Holmes SJ, Granoff PD, Lucas AH. Effect of immunity to the carrier protein on antibody responses to Haemophilus influenzae type b conjugate vaccines. Vaccine (1993) 11:S46-51. doi:10.1016/0264-410X(93)90160-Y
67. Rubins JB, Alter M, Loch J, Janoff EN. Determination of antibody responses of elderly adults to all 23 capsular polysaccharides after pneumococcal vaccination. Infect Immun (1999) 67:5979-84.
68. Rubins JB, Puri AK, Loch J, Charboneau D, MacDonald R, Opstad N, et al. Magnitude, duration, quality, and function of pneumococcal vaccine responses in elderly adults. J Infect Dis (1998) 178:431-40. doi:10.1086/515644
69. Christenson B, Lundbergh P, Hedlund J, örtqvist Å. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study. Lancet (2001) 357:1008-11. doi:10.1016/S0140-6736(00)04237-9
70. Vila-Córcoles A, Ochoa-Gondar O, Ansa X, Vilanova A, Rodríguez T, Llor C. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clin Infect Dis (2006) 43:860-8. doi:10.1086/507340
71. Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet (2005) 366:1165-74. doi:10.1016/S0140-6736(05)67339-4
72. Goldblatt D, Hussain M, Andrews N, Ashton L, Virta C, Melegaro A, et al. Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: a longitudinal household study. J Infect Dis (2005) 192:387-93. doi:10.1086/431524
73. Simell B, Lahdenkari M, Reunanen A, Käyhty H, Väkeväinen M. Effects of ageing and gender on naturally acquired antibodies to pneumococcal capsular polysaccharides and virulence-associated proteins. Clin Vaccine Immunol (2008) 15:1391-7. doi:10.1128/CVI.00110-08
74. Koivula M, Stén M, Leinonen M, Mäkelä M, Helena P. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am J Med (1997) 103:281-90. doi:10.1016/S0002-9343(97)00149-6
75. Honkanen PO, Keistinen T, Miettinen L, Herva E, Sankilampi U, Läärä E, et al. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine (1999) 17:2493-500. doi:10.1016/S0264-410X(99)00069-9
76. Kelly DF, Moxon ER, Pollard AJ. Haemophilus influenzae type b conjugate vaccines. Immunology (2004) 113:163-74. doi:10.1111/j.1365-2567.2004.01971.x
77. Käyhty H. Difficulties in establishing a serological correlate of protection after immunization with Haemophilus influenzae conjugate vaccines. Biologicals (1994) 22:397-402. doi:10.1006/biol.1994.1062
78. Lucas AH, Reason DC. Aging and the immune response to the Haemophilus influenzae type b capsular polysaccharide: retention of the dominant idiotype and antibody function in the elderly. Infect Immun (1998) 66:1752-4.
79. Kantor E, Luxenberg JS, Lucas AH, Granoff DM. Phase I study of the immunogenicity and safety of conjugated Hemophilus influenzae type b vaccines in the elderly. Vaccine (1997) 15:129-32. doi:10.1016/S0264-410X(96)00164-8
80. Ghia P, Prato G, Scielzo C, Stella S, Geuna M, Guida G, et al. Monoclonal CD5 and CD5-B-lymphocyte expansions are frequent in the peripheral blood of the elderly. Blood (2004) 103:2337-42. doi:10.1182/blood-2003-09-3277
81. Rawstron AC, Davies FE, DasGupta R, Ashcroft AJ, Patmore R, Drayson MT, et al. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood (2002) 100:3095-100. doi:10.1182/blood-2001-12-0297
82. Hijmans W, Radil J, Bottazzo GF, Doniach D. Autoantibodies in highly aged humans. Mech Ageing Dev (1984) 26:83-9. doi:10.1016/0047-6374(84)90167-2
83. Nikolich-Žugich J. T cell aging naive but not young. J Exp Med (2005) 201:837-40. doi:10.1084/jem.20050341
84. Lee N, Shin MS, Kang I. T-cell biology in aging, with a focus on lung disease. J Gerontol A Biol Sci Med Sci (2012) 67:254-63. doi:10.1093/gerona/glr237
85. Henson SM, Akbar AN. Memory T-cell homeostasis and senescence during aging. Memory T Cells Anonymous. New York: Springer (2010). p. 189-97.
86. Gregersen H, Madsen KM, Sorensen HT, Schonheyder HC, Ibsen JS, Dahlerup JF. The risk of bacteremia in patients with monoclonal gammopathy of undetermined significance. Eur J Haematol (1998) 61:140-4. doi:10.1111/j.1600-0609.1998.tb01075.x
87. Gregersen H, Mellemkjaer L, Ibsen JS, Dahlerup JF, Thomassen L, Sorensen HT. The impact of M-component type and immunoglobulin concentration on the risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance. Haematologica (2001) 86:1172-9.
88. Baldini L, Guffanti A, Cesana BM, Colombi M, Chiorboli O, Damilano I, et al. Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy. Blood (1996) 87:912-8.
89. Cesana C, Klersy C, Barbarano L, Nosari AM, Crugnola M, Pungolino E, et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol (2002) 20:1625-34. doi:10.1200/JCO.20.6.1625
90. Kyrtsonis MC, Mouzaki A, Maniatis A. Mechanisms of polyclonal hypogammaglobulinaemia in multiple myeloma (MM). Med Oncol (1999) 16:73-7. doi:10.1007/BF02785839
91. Perez-Persona E, Mateo G, Garcia-Sanz R, Mateos MV, de Las Heras N, de Coca AG, et al. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. Br J Haematol (2010) 148:110-4. doi:10.1111/j.1365-2141.2009.07929.x
92. Katzmann JA, Clark R, Kyle RA, Larson DR, Therneau TM, Melton LJ III, et al. Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS. Leukemia (2013) 27:208-12. doi:10.1038/leu.2012.189
93. Tete SM, Wilting KR, Horst G, Klijn MA, Westra J, de Haan A, et al. IgG antibody and TH1 immune responses to influenza vaccination negatively correlate with M-protein burden in monoclonal gammopathy of undetermined significance. Hematol Leuk (2013) 1:3. doi:10.7243/2052-434X-1-3
94. Harrison SJ, Franklin IM, Campbell JD. Enumeration of blood dendritic cells in patients with multiple myeloma at presentation and through therapy. Leuk Lymphoma (2008) 49:2272-83. doi:10.1080/10428190802464729
95. Pessoa de Magalhães R, Vidriales M, Paiva B, Fernandez-Gimenez C, García-Sanz R, Mateos M, et al. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica (2013) 98:79-86. doi:10.3324/haematol.2012.067272
96. Olteanu H, Wang HY, Chen W, McKenna RW, Karandikar NJ. Immunophenotypic studies of monoclonal gammopathy of undetermined significance. BMC Clin Pathol (2008) 8:13. doi:10.1186/1472-6890-8-13
97. de Tute RM, Jack AS, Child JA, Morgan GJ, Owen RG, Rawstron AC. A single-tube six-colour flow cytometry screening assay for the detection of minimal residual disease in myeloma. Leukemia (2007) 21:2046-9. doi:10.1038/sj.leu.2404815
98. Marsee DK, Li B, Dorfman DM. Single tube, six-color flow cytometric analysis is a sensitive and cost-effective technique for assaying clonal plasma cells. Am J Clin Pathol (2010) 133:694-9. doi:10.1309/AJCPKKNPMLWX9ZXB
99. Kobayashi S, Hyo R, Amitani Y, Tanaka M, Hashimoto C, Sakai R, et al. Four-color flow cytometric analysis of myeloma plasma cells. Am J Clin Pathol (2006) 126:908-15. doi:10.1309/VWXARAAG9DAPQ31Y
100. Paiva B, Pérez-Andrés M, Vidriales M, Almeida J, de Las Heras N, Mateos M, et al. Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs. myeloma. Leukemia (2011) 25:697-706. doi:10.1038/leu.2010.320
101. Kovarova L, Buresova I, Buchler T, Suska R, Pour L, Zahradova L, et al. Phenotype of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance. Neoplasma (2009) 56:526-32. doi:10.4149/neo_2009_06_526
102. Kumar S, Rajkumar SV, Kyle RA, Lacy MQ, Dispenzieri A, Fonseca R, et al. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. J Clin Oncol (2005) 23:5668-74. doi:10.1200/JCO.2005.03.159
103. Billadeau D, Van Ness B, Kimlinger T, Kyle RA, Therneau TM, Greipp PR, et al. Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma. Blood (1996) 88:289-96.
104. Rawstron AC, Owen RG, Davies FE, Johnson RJ, Jones RA, Richards SJ, et al. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. Br J Haematol (1997) 97:46-55. doi:10.1046/j.1365-2141.1997.72653.x
105. Ocqueteau M, Orfao A, Almeida J, Bladé J, Gonzalez M, García-Sanz R, et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol (1998) 152:1655.
106. Nowakowski GS, Witzig TE, Dingli D, Tracz MJ, Gertz MA, Lacy MQ, et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood (2005) 106:2276-9. doi:10.1182/blood-2005-05-1858
107. Witzig T, Gertz M, Lust J, Kyle R, O'Fallon W, Greipp P. Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. Blood (1996) 88:1780-7.
108. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med (2002) 346:564-9. doi:10.1056/NEJMoa01133202
109. Raitakari M, Brown RD, Gibson J, Joshua DE. T cells in myeloma. Hematol Oncol (2003) 21:33-42. doi:10.1002/hon.704
110. Murakami H, Ogawara H, Hiroshi H. Th1/Th2 cells in patients with multiple myeloma. Hematology (2004) 9:41-5. doi:10.1080/10245330310001652437
111. Cousins D, Lee T, Staynov D. Cytokine coexpression during human Th1/Th2 cell differentiation: direct evidence for coordinated expression of Th2 cytokines. J Immunol (2002) 169:2498-506. doi:10.4049/jimmunol.169.5.2498
112. Glimcher LH, Murphy KM. Lineage commitment in the immune system: the T helper lymphocyte grows up. Genes Dev (2000) 14:1693-711. doi:10.1101/gad.14.14.1693
113. Zhang XL, Komada Y, Chipeta J, Li QS, Inaba H, Azuma E, et al. Intracellular cytokine profile of T cells from children with acute lymphoblastic leukemia. Cancer Immunol Immunother (2000) 49:165-72. doi:10.1007/s002620050616
114. Mori T, Takada R, Watanabe R, Okamoto S, Ikeda Y. T-helper (Th)1/Th2 imbalance in patients with previously untreated B-cell diffuse large cell lymphoma. Cancer Immunol Immunother (2001) 50:566-8. doi:10.1007/s00262-001-0232-8
115. Frassanito M, Cusmai A, Dammacco F. Deregulated cytokine network and defective Th1 immune response in multiple myeloma. Clin Exp Immunol (2001) 125:190-7. doi:10.1046/j.1365-2249.2001.01582.x
116. Maecker B, Anderson KS, von Bergwelt-Baildon MS, Weller E, Vonderheide RH, Richardson PG, et al. Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma. Br J Haematol (2003) 121:842-8. doi:10.1046/j.1365-2141.2003.04375.x
117. O'Garra A, Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med (2004) 10:801-5. doi:10.1038/nm0804-801
118. Buckner JH, Ziegler SF. Regulating the immune system: the induction of regulatory T cells in the periphery. Arthritis Res Ther (2004) 6:215-24. doi:10.1186/ar1226
119. Bacchetta R, Gregori S, Roncarolo M. CD4 regulatory T cells: mechanisms of induction and effector function. Autoimmun Rev (2005) 4:491-6. doi:10.1016/j.autrev.2005.04.005
120. Niederkorn JY. Emerging concepts in CD8 T regulatory cells. Curr Opin Immunol (2008) 20:327-31. doi:10.1016/j.coi.2008.02.003
121. Thomson CW, Lee BP, Zhang L. Double-negative regulatory T cells. Immunol Res (2006) 35:163-77. doi:10.1385/IR:35:1:163
122. Romagnani S. Regulation of the T cell response. Clin Exp Allergy (2006) 36:1357-66. doi:10.1111/j.1365-2222.2006.02606.x
123. Vieira PL, Christensen JR, Minaee S, O'Neill EJ, Barrat FJ, Boonstra A, et al. IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4 CD25 regulatory T cells. J Immunol (2004) 172:5986-93. doi:10.4049/jimmunol.172.10.5986
124. Prabhala R, Neri P, Bae J, Tassone P, Shammas M, Allam C, et al. Dysfunctional T regulatory cells in multiple myeloma. Blood (2006) 107:301-4.
125. Beyer M, Kochanek M, Giese T, Endl E, Weihrauch M, Knolle P, et al. In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood (2006) 107:3940-9. doi:10.1182/blood-2005-09-3671
126. Feyler S, von Lilienfeld-Toal M, Jarmin S, Marles L, Rawstron A, Ashcroft A, et al. CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(-)CD8(-)alphabetaTCR(+) double negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. Br J Haematol (2009) 144:686-95. doi:10.1111/j.1365-2141.2008.07530.x
127. Giannopoulos K, Kaminska W, Hus I, Dmoszynska A. The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma. Br J Cancer (2012) 106:546-52. doi:10.1038/bjc.2011.575
128. Sakaguchi S, Setoguchi R, Yagi H, Nomura T. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in self-tolerance and autoimmune disease. Curr Top Microbiol Immunol (2006) 305:51-66.
129. Ratta M, Fagnoni F, Curti A, Vescovini R, Sansoni P, Oliviero B, et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood (2002) 100:230-7. doi:10.1182/blood.V100.1.230
130. Brimnes MK, Svane IM, Johnsen HE. Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma. Clin Exp Immunol (2006) 144:76-84. doi:10.1111/j.1365-2249.2006.03037.x
131. Brown RD, Pope B, Murray A, Esdale W, Sze DM, Gibson J, et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood (2001) 98:2992-8. doi:10.1182/blood.V98.10.2992
132. Brown R, Murray A, Pope B, Sze DM, Gibson J, Ho PJ, et al. Either interleukin-12 or interferon-gamma can correct the dendritic cell defect induced by transforming growth factor beta in patients with myeloma. Br J Haematol (2004) 125:743-8. doi:10.1111/j.1365-2141.2004.04984.x
133. Straube C, Wehner R, Wendisch M, Bornhauser M, Bachmann M, Rieber EP, et al. Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells. Leukemia (2007) 21:1464-71. doi:10.1038/sj.leu.2404734
134. Nencioni A, Garuti A, Schwarzenberg K, Cirmena G, Dal Bello G, Rocco I, et al. Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells. Eur J Immunol (2006) 36:681-9. doi:10.1002/eji.200535298
135. Chauhan D, Singh AV, Brahmandam M, Carrasco R, Bandi M, Hideshima T, et al. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell (2009) 16:309-23. doi:10.1016/j.ccr.2009.08.019
136. Bae J, Prabhala R, Munshi NC. Dendritic cells and peptide-based vaccine in multiple myeloma. In: Munshi N, Anderson K, editors. Advances in Biology and Therapy of Multiple Myeloma. New York: Springer (2013). p. 131-54.
137. Schultze J, Nadler LM, Gribben JG. B7-mediated costimulation and the immune response. Blood Rev (1996) 10:111-27. doi:10.1016/S0268-960X(96)90040-5
138. Draghi M, Pashine A, Sanjanwala B, Gendzekhadze K, Cantoni C, Cosman D, et al. NKp46 and NKG2D recognition of infected dendritic cells is necessary for NK cell activation in the human response to influenza infection. J Immunol (2007) 178:2688-98. doi:10.4049/jimmunol.178.5.2688
139. Bhardwaj N, Bender A, Gonzalez N, Bui LK, Garrett MC, Steinman RM. Influenza virus-infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8 T cells. J Clin Invest (1994) 94:797. doi:10.1172/JCI117399
140. Garcia-Sanz R, Gonzalez M, Orfao A, Moro MJ, Hernandez JM, Borrego D, et al. Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications. Br J Haematol (1996) 93:81-8. doi:10.1046/j.1365-2141.1996.4651006.x
141. Osterborg A, Nilsson B, Bjorkholm M, Holm G, Mellstedt H. Natural killer cell activity in monoclonal gammopathies: relation to disease activity. Eur J Haematol (1990) 45:153-7. doi:10.1111/j.1600-0609.1990.tb00443.x
142. Gonzalez M, San Miguel JF, Gascon A, Moro MJ, Hernandez JM, Ortega F, et al. Increased expression of natural-killer-associated and activation antigens in multiple myeloma. Am J Hematol (1992) 39:84-9. doi:10.1002/ajh.2830390203
143. Jurisic V, Srdic T, Konjevic G, Markovic O, Colovic M. Clinical stage-depending decrease of NK cell activity in multiple myeloma patients. Med Oncol (2007) 24:312-7. doi:10.1016/S0145-2126(07)70390-9
144. Costello RT, Boehrer A, Sanchez C, Mercier D, Baier C, Le Treut T, et al. Differential expression of natural killer cell activating receptors in blood vs. bone marrow in patients with monoclonal gammopathy. Immunology (2013) 139:338-41. doi:10.1111/imm.12082
145. Carbone E, Neri P, Mesuraca M, Fulciniti M, Otsuki T, Pende D, et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood (2005) 105:251-8. doi:10.1182/blood-2004-04-1422
146. Jinushi M, Vanneman M, Munshi NC, Tai YT, Prabhala RH, Ritz J, et al. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci U S A (2008) 105:1285-90. doi:10.1073/pnas.0711293105
147. von Lilienfeld-Toal M, Frank S, Leyendecker C, Feyler S, Jarmin S, Morgan R, et al. Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked. Cancer Immunol Immunother (2010) 59:829-39. doi:10.1007/s00262-009-0807-3
148. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood (2001) 98:210-6. doi:10.1182/blood.V98.1.210
149. Jungkunz-Stier I, Zekla M, Stuhmer T, Einsele H, Seggewiss Bernhardt R. Modulation of NK cell effector functions through lenalidomide/dasatinib and their combined effects against multiple myeloma cells. Leuk Lymphoma (2014) 55:168-76. doi:10.3109/10428194.2013.794270
150. Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol (2007) 138:563-79. doi:10.1111/j.1365-2141.2007.06705.x
151. Campbell JD, Cook G, Robertson SE, Fraser A, Boyd KS, Gracie JA, et al. Suppression of IL-2-induced T cell proliferation and phosphorylation of STAT3 and STAT5 by tumor-derived TGF beta is reversed by IL-15. J Immunol (2001) 167:553-61. doi:10.4049/jimmunol.167.1.553
152. Dankbar B, Padró T, Leo R, Feldmann B, Kropff M, Mesters RM, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood (2000) 95:2630-6.
153. Ladetto M, Vallet S, Trojan A, Dell'Aquila M, Monitillo L, Rosato R, et al. Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome. Blood (2005) 105:4784-91. doi:10.1182/blood-2004-11-4201
154. Gross P, Hermogenes A, Sacks H, Lau J, Levandowski R. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med (1995) 123:518-27. doi:10.7326/0003-4819-123-7-199510010-00008
155. Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull (1979) 35:69-75.
156. Robertson J, Nagesh K, Jowitt S, Dougal M, Anderson H, Mutton K, et al. Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. Br J Cancer (2000) 82:1261-5. doi:10.1054/bjoc.1999.1088
157. Ljungman P, Nahi H, Linde A. Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study. Br J Haematol (2005) 130:96-8. doi:10.1111/j.1365-2141.2005.05582.x
158. Kroon F, van Dissel J, de Jong J, van Furth R. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes. AIDS (1994) 8:469-76.
159. Engelhard D, Nagler A, Hardan I, Morag A, Aker M, Baciu H, et al. Antibody response to a two-dose regimen of influenza vaccine in allogenic T cell-depleted and autologous BMT recipients. Bone Marrow Transplant (1993) 11:1-5.
160. Rapezzi D, Sticchi L, Racchi O, Mangerini R, Ferraris AM, Gaetani GF. Influenza vaccine in chronic lymphoproliferative disorders and multiple myeloma. Eur J Haematol (2003) 70:225-30. doi:10.1034/j.1600-0609.2003.00028.x
161. Schiffman G, Douglas RM, Bonner MJ, Robbins M, Austrian R. A radioimmunoassay for immunologic phenomena in pneumococcal disease and for the antibody response to pneumococcal vaccines. I. Method for the radioimmunoassay of anticapsular antibodies and comparison with other techniques. J Immunol Methods (1980) 33:133-44. doi:10.1016/S0022-1759(80)80004-4
162. Landesman S, Schiffman G. Assessment of the antibody response to pneumococcal vaccine in high-risk populations. Rev Infect Dis (1981) 3(Suppl):S184-97. doi:10.1093/clinids/3.Supplement_1.S184
163. Schmid GP, Smith RP, Baltch AL, Hall CA, Schiffman G. Antibody response to pneumococcal vaccine in patients with multiple myeloma. J Infect Dis (1981) 143:590-7. doi:10.1093/infdis/143.4.590
164. Birgens H, Espersen F, Hertz J, Pedersen F, Drivsholm A. Antibody response to pneumococcal vaccination in patients with myelomatosis. Scand J Haematol (1983) 30:324-30. doi:10.1111/j.1600-0609.1983.tb01500.x
165. Lazarus HM, Lederman M, Lubin A, Herzig RH, Schiffman G, Jones P, et al. Pneumococcal vaccination: the response of patients with multiple myeloma. Am J Med (1980) 69:419-23. doi:10.1016/0002-9343(80)90014-5
166. Hargreaves R, Lea J, Griffiths H, Faux J, Holt J, Reid C, et al. Immunological factors and risk of infection in plateau phase myeloma. J Clin Pathol (1995) 48:260-6. doi:10.1136/jcp.48.3.260
167. Nix EB, Hawdon N, Gravelle S, Biman B, Brigden M, Malik S, et al. Risk of invasive Haemophilus influenzae type b (Hib) disease in adults with secondary immunodeficiency in the post-Hib vaccine era. Clin Vaccine Immunol (2012) 19:766-71. doi:10.1128/CVI.05675-11
168. Small TN, Keever CA, Weiner-Fedus S, Heller G, O'Reilly RJ, Flomenberg N. B-cell differentiation following autologous, conventional, or T-cell depleted bone marrow transplantation: a recapitulation of normal B-cell ontogeny. Blood (1990) 76:1647-56.
169. Storek J, Saxon A. Reconstitution of B cell immunity following bone marrow transplantation. Bone Marrow Transplant (1992) 9:395-408.
170. Witherspoon RP, Lum LG, Storb R. Immunologic reconstitution after human marrow grafting. Semin Hematol (1984) 21:2-10.
171. Fox R, McMillan R, Spruce W, Tani P, Mason D. Analysis of T lymphocytes after bone marrow transplantation using monoclonal antibodies. Blood (1982) 60:578-82.
172. Ault KA, Antin JH, Ginsburg D, Orkin SH, Rappeport JM, Keohan ML, et al. Phenotype of recovering lymphoid cell populations after marrow transplantation. J Exp Med (1985) 161:1483-502. doi:10.1084/jem.161.6.1483
173. Gandhi MK, Egner W, Sizer L, Inman I, Zambon M, Craig JI, et al. Antibody responses to vaccinations given within the first two years after transplant are similar between autologous peripheral blood stem cell and bone marrow transplant recipients. Bone Marrow Transplant (2001) 28:775-81. doi:10.1038/sj.bmt.1703239
174. Avetisyan G, Aschan J, Hassan M, Ljungman P. Evaluation of immune responses to seasonal influenza vaccination in healthy volunteers and in patients after stem cell transplantation. Transplantation (2008) 86:257-63. doi:10.1097/TP.0b013e3181772a75
175. Ljungman P, Avetisyan G. Influenza vaccination in hematopoietic SCT recipients. Bone Marrow Transplant (2008) 42:637-41. doi:10.1038/bmt.2008.264
176. Ljungman P. Immunization of transplant recipients. Bone Marrow Transplant (1999) 23:635-6. doi:10.1038/sj.bmt.1701641
177. Hinge M, Ingels HA, Slotved HC, Molle I. Serologic response to a 23-valent pneumococcal vaccine administered prior to autologous stem cell transplantation in patients with multiple myeloma. APMIS (2012) 120:935-40. doi:10.1111/j.1600-0463.2012.02922.x
178. Lortan JE, Vellodi A, Jurges ES, Hugh-Jones K. Class- and subclass-specific pneumococcal antibody levels and response to immunization after bone marrow transplantation. Clin Exp Immunol (1992) 88:512-9. doi:10.1111/j.1365-2249.1992.tb06480.x
179. Parkkali T, Kayhty H, Ruutu T, Volin L, Eskola J, Ruutu P. A comparison of early and late vaccination with Haemophilus influenzae type b conjugate and pneumococcal polysaccharide vaccines after allogenic BMT. Bone Marrow Transplant (1996) 18:961-7.
180. Rapoport AP, Stadtmauer EA, Aqui N, Badros A, Cotte J, Chrisley L, et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med (2005) 11:1230-7. doi:10.1038/nm1310
181. Stadtmauer EA, Vogl DT, Luning Prak E, Boyer J, Aqui NA, Rapoport AP, et al. Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial. Blood (2011) 117:63-71. doi:10.1182/blood-2010-07-296822